Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vor BiopharmaVOR +0.65%33 Cash-to-Debt is 162.02 as of Jun. 2026, which is 2998% above its 10-year median of 5.23. GuruFocus rates VOR with a GF Score™ of 33/100. The stock has 4 warning signs investors should review. Among 1,393 Biotechnology companies, Vor Biopharma ranks better than 79.76% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Vor Biopharma's cash to debt ratio for the quarter that ended in Jun. 2026 was 162.02.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Vor Biopharmacould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Vor Biopharma's Cash-to-Debt or its related term are showing as below:
VOR'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.21 Med: 5.23 Max: No Debt
Current: 162.02
During the past 8 years, Vor Biopharma's highest Cash to Debt Ratio was No Debt. The lowest was 0.21. And the median was 5.23.
VOR's Cash-to-Debt is ranked better than 79.76% of 1393
companies
in the Biotechnology industry
Industry Median: 7.03
vs VOR: 162.02
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Vor Biopharma Cash-to-Debt Related Terms
Vor Biopharma Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Vor Biopharma's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Vor Biopharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vor Biopharma Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vor Biopharma's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Vor Biopharma's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vor Biopharma (VOR) has a Cash-to-Debt of 162.02 as of Jun. 2026. This is 2998% above median its historical median of 5.23. Over the past decade, Vor Biopharma's Cash-to-Debt has ranged from 0.21 to 10,000.00. According to the industry distribution chart, Vor Biopharma ranks #282 out of 1393 companies in the Biotechnology industry, placing it in the top 20.2%.
Is Vor Biopharma's Cash-to-Debt too high?
Vor Biopharma's current Cash-to-Debt of 162.02 is 2998% above median its 10-year median of 5.23. Over the past 10 years, this metric has ranged from a low of 0.21 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 7.03. Vor Biopharma's value of 162.02 is 2204.7% above this industry median. Based on the distribution chart, Vor Biopharma ranks #282 out of 1393 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vor Biopharma has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Vor Biopharma's Cash-to-Debt compare to OMER and MGTX?
According to the Biotechnology industry distribution chart, Vor Biopharma ranks #282 out of 1393 companies for Cash-to-Debt. This places Vor Biopharma in the top 20% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 7.03. Vor Biopharma's value of 162.02 is 2204.7% above this benchmark. Historically, Vor Biopharma's own Cash-to-Debt has ranged from 0.21 to 10,000.00 over the past decade. While the company's 10-year median is 5.23 vs. the industry median of 7.03, Vor Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.03, based on 1,393 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vor Biopharma's current Cash-to-Debt of 162.02 is 2204.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vor Biopharma's current Cash-to-Debt is 162.02, which is 2998% above median its own 10-year median of 5.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vor Biopharma stock overvalued right now?
Vor Biopharma (VOR) has a current Cash-to-Debt of 162.02. The current Cash-to-Debt is 162.02, which is 2998% above median its 10-year median of 5.23 and 2204.7% above the Biotechnology industry median of 7.03. Vor Biopharma's overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Vor Biopharma (VOR), the current Cash-to-Debt is 162.02 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.
33GF Score
Get the complete analysis for VOR
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VOR has been successfully added to your 
